NYSE:BTX

Brooklyn ImmunoTherapeutics Stock Forecast, Price & News

$0.55

0.00 (0.00%)

(As of 06/29/2022 04:00 PM ET)

Add

Compare

Today's Range: $0.52
▼
$0.57
50-Day Range: $0.48
▼
$1.35
52-Week Range: $0.46
▼
$21.03

Volume: 260,463 shs
Average Volume: 507,665 shs
Market Capitalization: $31.60 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

30 days | 90 days | 365 days | Advanced Chart

Receive BTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Brooklyn ImmunoTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

BTX Stock Forecast (MarketRank)

Overall MarketRank^™

0.00 out of 5 stars

Medical Sector

1420th out of 1,433 stocks

Biotechnology Industry

6th out of 8 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Brooklyn ImmunoTherapeutics.

0.0 Community Rank

Outperform Votes
Brooklyn ImmunoTherapeutics has received 0 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Brooklyn ImmunoTherapeutics has received 2 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Brooklyn ImmunoTherapeutics has received 100.00% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Brooklyn ImmunoTherapeutics and other stocks. Vote “Outperform” if you believe BTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Brooklyn ImmunoTherapeutics does not currently pay a dividend.
Dividend Growth
Brooklyn ImmunoTherapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Brooklyn ImmunoTherapeutics insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

About Brooklyn ImmunoTherapeutics (NYSE:BTX)

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.

June 4, 2022 | americanbankingnews.com

Brooklyn ImmunoTherapeutics (NYSE:BTX) Trading Down 0.8%

See More Headlines

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:BTX
CUSIP: N/A
CIK: 748592
Web: www.brooklynitx.com
Phone: 212 582 1199
Fax: N/A
Employees: 10
Year Founded: N/A

Company Calendar

Last Earnings: 4/15/2022
Today: 6/29/2022

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 57,452,000
Free Float: N/A
Market Cap: $31.60 million
Optionable: Optionable
Beta: N/A

Brooklyn ImmunoTherapeutics Frequently Asked Questions

How has Brooklyn ImmunoTherapeutics' stock price performed in 2022?: Brooklyn ImmunoTherapeutics' stock was trading at $2.05 on January 1st, 2022. Since then, BTX stock has decreased by 73.2% and is now trading at $0.55.
View the best growth stocks for 2022 here.
How were Brooklyn ImmunoTherapeutics' earnings last quarter?: Brooklyn ImmunoTherapeutics, Inc. (NYSE:BTX) announced its quarterly earnings data on Friday, April, 15th. The company reported ($0.16) earnings per share (EPS) for the quarter.
View Brooklyn ImmunoTherapeutics' earnings history.
Who are Brooklyn ImmunoTherapeutics' key executives?: Brooklyn ImmunoTherapeutics' management team includes the following people:
Dr. Kevin A. D'Amour Ph.D., Chief Scientific Officer (Age 49, Pay $448.62k)
Dr. Roger Sidhu M.D., Chief Medical Officer (Age 46, Pay $501.95k)
Dr. Matthew Angel Ph.D., CEO & Director (Age 41)
Mr. Andrew C. Jackson, Chief Financial Officer (Age 53)
Dr. Monil Shah M.B.A., Pharm.D., Chief Operating Officer
Ms. Sandra M. Gurrola, Principal Accounting Officer & VP of Fin. (Age 55)
Mr. Jay Sial, Chief Admin. Officer (Age 57)
Ms. Lynn Sadowski Mason M.S., Exec. VP of Clinical Operations (Age 43)
Ms. Susan McClatchey, VP & Head of Quality
Who are some of Brooklyn ImmunoTherapeutics' key competitors?: Some companies that are related to Brooklyn ImmunoTherapeutics include Tiziana Life Sciences (TILS), ImmunoPrecise Antibodies (IPA), Novacyt (NCYT), Verseon (VSN), Scancell (SCLP), Faron Pharmaceuticals Oy (FARN), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), Aptose Biosciences (APS), Arecor Therapeutics (AREC), e-therapeutics (ETX), Mereo BioPharma Group plc (MPH.L) (MPH), Medicenna Therapeutics (MDNA) and IntelGenx Technologies (IGX).
View all of BTX's competitors.

What is Brooklyn ImmunoTherapeutics' stock symbol?: Brooklyn ImmunoTherapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "BTX."
How do I buy shares of Brooklyn ImmunoTherapeutics?: Shares of BTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Brooklyn ImmunoTherapeutics' stock price today?: One share of BTX stock can currently be purchased for approximately $0.55.
How much money does Brooklyn ImmunoTherapeutics make?: Brooklyn ImmunoTherapeutics (NYSE:BTX) has a market capitalization of $31.60 million.
How many employees does Brooklyn ImmunoTherapeutics have?: Brooklyn ImmunoTherapeutics employs 10 workers across the globe.
How can I contact Brooklyn ImmunoTherapeutics?: The official website for Brooklyn ImmunoTherapeutics is www.brooklynitx.com. The company can be reached via phone at 212 582 1199.

This page (NYSE:BTX) was last updated on 6/29/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms

Just $1.00 for your first month.

Brooklyn ImmunoTherapeutics Stock Forecast, Price & News

Receive BTX Stock News and Ratings via Email